Universal Health Coverage: Department of Communicable Disease Prevention and Control, World Health Organization Regional Office for the Eastern Mediterranean, Cairo, Egypt.
Independent Consultant, Rabat, Morocco.
Lancet Gastroenterol Hepatol. 2022 Sep;7(9):862-870. doi: 10.1016/S2468-1253(22)00082-6. Epub 2022 Jul 9.
The WHO Global Health Sector Strategy and hepatitis regional action plan for the WHO Eastern Mediterranean Region (EMR) proposed strategic directions for countries to progress towards the elimination of viral hepatitis by 2030. In 2019, we reviewed progress to gain a picture of current pressures and identify priority actions for member states to reach this goal. We collected data from country, regional, and global reports published in 2015-19, questionnaires completed by countries, and convened a regional consultation with programme managers and partners. We analysed these data along three thematic areas: governance and finance, strategic information, and service delivery. 15 of the 22 EMR countries completed the review. Of these, 10 (67%) had a national strategy and six (40%) allocated funds to it. 11 (73%) countries had testing and treatment guidelines in line with WHO recommendations. Ten (67%) countries had burden and coverage estimates, four (27%) reported on the cascade of care for hepatitis C virus (HCV), three (20%) reported on the cascade of care for hepatitis B (HBV), and three (20%) had mortality estimates. By 2019, the regional hepatitis B vaccination coverage among infants was 82% for the third dose and 33% for the timely birth dose. For harm reduction, 27 syringes were distributed per injecting drug user per year. Between 2015 and 2019, HCV diagnosis increased from 18% to 33% and treatment for hepatitis C increased from 12% to 26%. Within the same time period, diagnosis of HBV diagnosis increased from 2% to 14% and treatment initiation increased from less than 1% to 2%. EMR countries made progress in governance, policy development, coverage of the third dose of the hepatitis B vaccine, and testing and treatment for HCV infection. However, birth dose vaccination, injection safety, harm reduction, and testing and treatment are limited by insufficient financing. Core interventions need to be included within national universal health coverage packages as an initial move towards elimination.
世界卫生组织全球卫生部门战略和东地中海区域(EMR)区域行动计划为各国提出了战略方向,以在 2030 年前实现消除病毒性肝炎。2019 年,我们审查了进展情况,以了解当前的压力情况,并确定成员国实现这一目标的优先行动。我们从 2015-19 年期间发表的国家、区域和全球报告、各国完成的调查问卷中收集数据,并与方案管理人员和合作伙伴举行了一次区域协商。我们沿着三个主题领域分析了这些数据:治理和资金、战略信息和服务提供。22 个东地中海区域国家中有 15 个完成了审查。其中,10 个(67%)国家有国家战略,6 个(40%)国家为其分配了资金。11 个(73%)国家有符合世卫组织建议的检测和治疗指南。10 个(67%)国家有负担和覆盖估计数,4 个(27%)国家报告了丙型肝炎病毒(HCV)护理链情况,3 个(20%)国家报告了乙型肝炎(HBV)护理链情况,3 个(20%)国家有死亡率估计数。到 2019 年,该区域婴儿第三剂乙肝疫苗及时接种率为 82%,及时出生接种率为 33%。在减少伤害方面,每个注射吸毒者每年分发 27 个注射器。2015 年至 2019 年期间,HCV 诊断率从 18%上升到 33%,丙型肝炎治疗率从 12%上升到 26%。同期,HBV 诊断率从 2%上升到 14%,治疗开始率从不到 1%上升到 2%。东地中海区域国家在治理、政策制定、第三剂乙肝疫苗接种覆盖率以及 HCV 感染检测和治疗方面取得了进展。然而,出生时接种疫苗、注射安全、减少伤害以及检测和治疗因资金不足而受到限制。核心干预措施需要作为迈向消除的初始步骤纳入国家全民健康覆盖一揽子计划中。